The 28.2% redemption rate is a strong negative signal — nearly a third of shareholders chose to exit rather than wait for a deal. The remaining trust is now materially smaller, reducing the SPAC's acquisition firepower. Monitor for a business combination announcement; the sponsor must now find a target that fits a smaller trust. If no deal is announced by mid-2026, the stock will likely trade closer to trust value minus expenses.
Price Chart
Executive Summary
Drugs Made In America Acquisition Corp. (DMAAR) held an extraordinary general meeting on April 27, 2026, where shareholders approved a 12-month extension of the deadline to complete a business combination from April 29, 2026 to April 29, 2027. In connection with the vote, holders of 9,440,230 shares (28.2% of outstanding) elected to redeem their shares for approximately $99.3 million ($10.52/share), leaving the SPAC with 24,276,913 shares outstanding and reduced trust assets. The extension buys time for a deal but the massive redemption signals significant shareholder skepticism about the company's prospects.
Key Facts
- Shareholders approved extension of business combination deadline from April 29, 2026 to April 29, 2027
- Holders of 9,440,230 shares (28.2% of outstanding) exercised redemption rights
- $99,336,016.67 (approximately $10.52 per share) removed from trust account to pay redeeming holders
- Post-redemption shares outstanding: 24,276,913, including 13,559,770 from IPO
- Extension Proposal received 18,906,281 FOR, 4,892,646 AGAINST, 0 ABSTAIN
- Board approved initial one-month extension to May 29, 2026
- Sponsor must deposit lesser of $300,000 or $0.04 per non-redeemed public share for each monthly extension
- Record date for meeting was April 7, 2026 with 33,517,143 ordinary shares outstanding
- 79.4% of voted shares supported the extension (18.9M of 23.8M voted)
Financial Impact
$99.3 million (approximately $10.52 per share) removed from trust account due to redemptions, representing 28.2% of pre-meeting shares
Risk Factors
- Continued redemptions in subsequent monthly extension periods could further deplete trust
- Reduced trust size limits potential acquisition targets and deal economics
- Sponsor may fail to fund monthly extension deposits, triggering liquidation
- High redemption rate signals lack of confidence in management's ability to find a quality deal
- If no business combination by April 29, 2027, SPAC must liquidate and return remaining trust to shareholders
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-051018 |
| Document: ea028877401ex3-1.htm | 0001213900-26-051018 |
| Document: 0001213900-26-051018-index-headers.html | 0001213900-26-051018 |
| Document: 0001213900-26-051018-index.html | 0001213900-26-051018 |
| Document: 0001213900-26-051018.txt | 0001213900-26-051018 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 5, 2026 24w ago | 8-K | — | awaiting T+20 | — | — |
May 1, 2026 25w ago | 8-K | — | awaiting T+20 | — | — |
Apr 8, 2026 28w ago | 8-K | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers